In survival analysis, high nuclear LOX expression in stage I to III cancers was correlated to poor overall cancer-specific survival (OS) (P = 0.017, Figure 4C) and disease free survival (DFS) (P = 0.049, Figure 4C). The gene discussed is LOX; the disease is cancer.